Puppy found suffering from heatstroke in hot car prompts warning from Beaver County Humane Society

A puppy suffering from heatstroke was rescued from a car in Hopewell Township, prompting a warning from the Beaver County Humane Society.
Last week, a 6-month-old Doberman named Atlas was found by Hopewell Township police in "extreme heat-related stress," locked in a car with a stopped engine and no access to water. Humane officers said Atlas had been locked inside for nearly 30 minutes before he was rescued, and when he got to the shelter, he was "dangerously" dehydrated, weak and trembling.
After the team at the humane society stabilized Atlas, he was taken to an emergency vet for overnight hospitalization. He was surrendered by his owner, and while he's in stable condition and recovering, the humane society says Atlas isn't out of the woods yet. He's made significant improvements in the past week, but the shelter doesn't know the full extent of the injuries caused by his prolonged exposure to extreme heat.
Humane society warns of leaving pets in hot cars
The Beaver County Humane Society is urging pet owners to protect their pets from the heat. If it's hot for you, that means it's even hotter for your pet. The warning comes as Pittsburgh has 90-degree temperatures in the forecast next week.
"We love summer as much as our pets, but we have a responsibility to protect them from unsafe conditions," Butler County Humane Society Executive Director Alison Yazer said in a news release. "Animals left in hot temperatures, especially enclosed spaces like cars, can develop heatstroke in as little as 15 minutes. Unfortunately, many pets don't survive it, even with veterinary intervention."
During hot temperatures, it's important to give pets plenty of fresh, clean and cool water to keep them hydrated. Time outside should be limited, and if you are heading out, make sure the asphalt isn't too hot, because it can burn a pet's paws.
Know the signs of overheating: excessive panting, trouble breathing, drooling and an increased heart rate. If your pet is collapsing, having a seizure or has bloody diarrhea or vomiting, then they may be experiencing a heat-related emergency.
Is it illegal to leave a pet in a hot car?
It's not illegal to leave your pet in a vehicle, but police officers, humane officers and animal control officers have the right to forcibly remove pets from cars if they have good-faith reason to believe the pet will suffer harm if not immediately removed.
Leaving a pet in a car in dangerous conditions could lead to charges of animal cruelty, neglect or abandonment, which, in Pennsylvania, is punishable by up to seven years in jail and as much as $15,000 in fines, the humane society says.
Earlier this month in Altoona, a man was charged with a felony count of animal cruelty after his dog, which was rescued from a hot truck, died on the way to the vet.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Medscape

2 hours ago

• Medscape

Smartphone-Based Home Albuminuria Testing Boosts Screening

TOPLINE: Screening for albuminuria, a key marker of cardiorenal risk, remains inadequate among patients with diabetes or hypertension. A smartphone-enabled home testing solution, evaluated in 4000 adults, effectively increased screening rates and enabled early diagnosis of kidney disease. METHODOLOGY: Regular albuminuria testing is recommended in high-risk patients with diabetes or hypertension to enable early detection and timely intervention for kidney and cardiovascular complications; however, screening levels remains suboptimal. Researchers randomly selected 4000 adults (mean age, 61 years; 49% women; 93% White) from a large Central Pennsylvania healthcare system who had not undergone albumin-creatinine ratio testing in the previous 12 months; half the patients in the cohort had hypertension without diabetes, and the remaining half had diabetes. Patients were provided with Minuteful Kidney, an FDA-cleared, smartphone-enabled home albuminuria screening kit. Results were delivered to participants via a smartphone application and to healthcare providers through electronic health records. The intervention group was propensity score-matched with a control group receiving usual care. TAKEAWAY: Completion rates for any albumin-creatinine ratio testing were significantly higher in the intervention group than in the control group (53.1% vs 21.2%; P < .001). The impact of the intervention on albumin-creatinine ratio testing completion was more pronounced among patients with hypertension without diabetes (completion rates, 53.4% in the intervention group vs 12.5% in the control group) than among those with diabetes (completion rates, 52.7% vs 30.0%). Over 270 days of follow-up, patients tested with Minuteful Kidney had higher rates of new diagnoses of proteinuria or kidney disease (4.0% vs 2.2%; P < .001). Patients with an abnormal albumin-creatinine ratio on the home-based test demonstrated greater engagement with primary care and nephrology services and were more likely to receive prescriptions for renin-angiotensin-aldosterone system inhibitors than were those with normal results. IN PRACTICE: "A smartphone-enabled home albuminuria test is effective in increasing albuminuria screening and diagnosis of kidney disease among high-risk individuals," the authors concluded. SOURCE: The study was led by Waleed Zafar in Danville, Pennsylvania. It was presented on June 20, 2025, at the 85th Scientific Sessions – American Diabetes Association held at the McCormick Place Convention Center, Chicago. LIMITATIONS: The abstract did not discuss any limitations. DISCLOSURES: Two authors disclosed receiving research support from various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

CBS News

2 hours ago

• CBS News

Widespread power outages from extreme heat not expected, Duquesne Light says

Summer is finally here, and the weather is nice, but the greater Pittsburgh area is bracing for a heat wave in the coming days, and that can pose dangers for your family and home. The sun is shining once again, and by Sunday, it's going to cause a scorcher, not just here, but across the country. Just as summer kicks off, so too are the 90s, and temperatures are feeling like the triple digits, and folks have mixed opinions. Ronel Alegiojo, who's visiting from Baltimore, Maryland, said things could be worse. "Oh, I'm 100% ready," Alegiojo said. "It's better than snow." Aundalynn Aljoe of DuBois felt the same. "Bring it on," Aljoe said. For Aljoe, it's a great change after the rainy, cloudy weather we've had. "I feel like we're kind of owed a little bit of sun and warmth. I'm excited for it," Aljoe said. However, the heat comes with some risks to your health, so stay hydrated and dress for the weather, and, at home, prepare for the unpredictable. Matt Neistein with Duquesne Light Company said they're not anticipating problems with a greater load on the electrical grid. "The data that we have right now says that there should not be any widespread outages, as it stands," Neistein said. Just in case, keep your devices charged and have an emergency kit with things like non-perishable food, water, and batteries. Residents are also advised to reduce their electricity use by using fans, closing doors to rooms, and unplugging appliances. "You can raise the thermostat a few degrees, particularly between 2 and 6 p.m., which is the time of highest usage," Neistein said. If your power does go out, report it as soon as possible, and keep your freezer and refrigerator doors closed. Also, be sure to check in on your older family, friends, and neighbors who live alone. Neistein said they'll be staffed up as a precaution. "I really hope we can just get this over with, but we still have July coming up, so we've got a long summer, and this is just the beginning," Alegiojo said.

Yahoo

3 hours ago

• Yahoo

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

Virtual webinar on June 23, 2025 at 8:00 am ET NEWTOWN SQUARE, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the Company will host a virtual investor event to discuss the firmonertinib clinical program for the treatment of EGFR PACC mutant non-small cell lung cancer (NSCLC) on June 23, 2025 at 8:00 am ET. To register for the event, please click here. About ArriVentArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team's deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization. About FirmonertinibFirmonertinib (formerly furmonertinib) is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. In March 2021, firmonertinib was approved in China for first-line advanced non-small-cell lung cancer (NSCLC) with EGFR exon 19 deletion or L858R mutations and for patients with previously treated locally advanced or metastatic NSCLC with EGFR T790M mutation, otherwise known as EGFR classical mutations. Firmonertinib was granted U.S. Food and Drug Administration Breakthrough Therapy Designation for the treatment of patients with previously untreated locally advanced or metastatic non-squamous NSCLC with EGFR exon 20 insertion mutations. Firmonertinib was also granted U.S. Food and Drug Administration Orphan Drug Designation for the treatment of non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations or human epidermal growth factor receptor 2 (HER2) mutations or HER4 mutations. Firmonertinib is currently being studied in a global Phase 3 trial for first-line NSCLC patients with EGFR exon 20 insertion mutations (FURVENT; NCT05607550) and in a global Phase 1b study, which includes a cohort evaluating firmonertinib in patients with EGFR PACC mutations (FURTHER; NCT05364073). In addition, firmonertinib is also being studied in a clinical combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations, in partnership with Beijing InnoCare Pharma Tech Co., Ltd. About EGFR mutant NSCLCGlobally, lung cancer is the leading cause of cancer-related deaths among men and women. NSCLC is the predominant subtype of lung cancer, accounting for approximately 85% of all cases. Mutational activation of the EGFR is a frequent and early event in the development of NSCLC. EGFR mutations are divided into classical and uncommon. EGFR exon 20 insertion mutations are a group of uncommon EGFR mutations and constitute approximately 9% of all EGFR mutations. PACC mutations are another group of uncommon EGFR mutations and represent approximately 12% of all EGFR mutations. Patients with NSCLC whose tumors harbor uncommon EGFR mutations have significantly lower life expectancy with available therapies and represent an area of unmet medical need. Forward-Looking Statements This press release includes certain disclosures that contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, activity of firmonertinib compared to available therapies, anticipated clinical milestones, including the top-line pivotal global Phase 3 data for firmonertinib in previously untreated NSCLC patients whose tumors contain EGFR exon 20 insertion mutations, expansion of firmonertinib into a pivotal trial for 1L EGFR PACC mutant NSCLC and the timing of the first patient enrolled in such study, participation in the global Phase 3 registrational study of firmonertinib in adjuvant uncommon mutant NSCLC, anticipated IND filings for ADC candidates, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Forward-looking statements are based on ArriVent's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled 'Risk Factors' in our annual report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission on March 3, 2025 and our other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and ArriVent undertakes no duty to update such information except as required under applicable law. Contact:Joyce AllaireLifeSci Advisors, LLCjallaire@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data